Late-phase clinical trial fails to increase overall survival rate for colorectal cancer.
|
Corporate raider shakes up biotech firm, becomes chair, and interim CEO resigns.
|
Drug maker spurns $17.4-billion unsolicited offer, saying it undervalues the company.
|
ImClone Systems and Bristol-Myers Squibb’s cancer drug gets approval for another type of head and neck cancer.
|
Amgen shares slip as the company posts disappointing earnings instead of much-anticipated data on its cancer drug.
|
Analysts hold little hope that cancer-focused drug company ImClone Systems will sell.
|
Biotech companies to pursue opportunity of $2-billion-per-year cancer drug.
|
Daniel Lynch resigns after taking the reins from the embattled Waksal brothers.
|
Analysts expect ImClone Systems’ drug Erbitux to be successful in its FDA application as a treatment for head and neck cancer.
|
A study shows Astrazeneca’s Iressa kills lung cancer cells with a particular mutation.
|